Tofacitinib Use in Adults with Chronic Inflammatory Disease During the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic: What Is Known So Far?

• Prif Awduron: Samantha Howland, MPharm (Awdur), J. Jasper Deuring, PhD (Awdur), Xiaofeng Zhou, PhD (Awdur), Yan Chen, MD, PhD (Awdur), Licia MH Mota, MD (Awdur), Ryan C. Ungaro, MD, MS (Awdur)
• Fformat: Llyfr
• Cyhoeddwyd: Elsevier, 2021-01-01T00:00:00Z.
• Pynciau: article
• Mynediad Ar-lein: Connect to this object online.

ABSTRACT: Background: Concerns have been raised that the risk of severe acute respiratory syndrome coronavirus 2 infection, or more severe or critical coronavirus disease 2019 (COVID-19), may be higher in immunocompromised individuals receiving immunomodulatory therapies compared with immunocompeten...